ArticleJournal of oncology2011
Potential markers for detection and monitoring of ovarian cancer.
Article in Journal of oncology, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 43 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
43 citing papers in PubMed, 111 citations in OpenAlex.
- Correlation between risk of malignancy index and histopathological findings in ovarian tumors.Journal of family medicine and primary care · 2025Article
- Risk of Ovarian Malignancy Algorithm and Pelvic Mass Score for the prediction of malignant ovarian tumors: a prospective comparative study.Journal of ultrasonography · 2024Article
- Tumor Markers in Differential Diagnosis of Benign Ovarian Masses.International journal of women's health · 2024Article
- Evaluating the Effectiveness of 2D and 3D CT Image Features for Predicting Tumor Response to Chemotherapy.Bioengineering (Basel, Switzerland) · 2023Article
- Identification of serum miR-1246 and miR-150-5p as novel diagnostic biomarkers for high-grade serous ovarian cancer.Scientific reports · 2023Article
- Lineage specific extracellular vesicle-associated protein biomarkers for the early detection of high grade serous ovarian cancer.Scientific reports · 2023Article
- VCAM-1 complements CA-125 in detecting recurrent ovarian cancer.Clinical proteomics · 2023Article
- Cancer-biomarkers associated with sex hormone receptors and recent therapeutic advancements: a comprehensive review.Medical oncology (Northwood, London, England) · 2023Review
- The Association Between Higher Expression of Talin-1 and the Reduced Survival Rate in Ovarian Serous Carcinoma Patients.Iranian journal of pathology · 2023Article
- Deregulated miRNA clusters in ovarian cancer: Imperative implications in personalized medicine.Genes & diseases · 2022Review
- Diagnostics of Ovarian Tumors in Postmenopausal Patients.Diagnostics (Basel, Switzerland) · 2022Review
- Recent findings on chimeric antigen receptor (CAR)-engineered immune cell therapy in solid tumors and hematological malignancies.Stem cell research & therapy · 2022Review
- Diagnostic value of risk of malignancy index in the clinical evaluation of ovarian mass.Molecular and clinical oncology · 2022Article
- Exosome-related protein CRABP2 is upregulated in ovarian carcinoma and enhances cell proliferation.Discover oncology · 2022Article
- Clinical significance of circulating tumor cell related markers in patients with epithelial ovarian cancer before and after adjuvant chemotherapy.Scientific reports · 2021Article
- Tubulin Beta 2C Chain (TBB2C), a Potential Marker of Ovarian Cancer, an Insight from Ovarian Cancer Proteome Profile.ACS omega · 2021Article
- Gamma-Synuclein Levels Are Elevated in Peritoneal Fluid of Patients with Endometriosis.Medical science monitor : international medical journal of experimental and clinical research · 2020Article
- Reducing Ovarian Cancer Mortality Through Early Detection: Approaches Using Circulating Biomarkers.Cancer prevention research (Philadelphia, Pa.) · 2020Review
- Discovery of Furanone-Based Radiopharmaceuticals for Diagnostic Targeting of COX-1 in Ovarian Cancer.ACS omega · 2019Article
- Urine Biomarkers for the Early Detection of Ovarian Cancer - Are We There Yet?Biomarkers in cancer · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This paper reviews current screening techniques as well as novel biomarkers and their potential role in early detection of ovarian cancer. Ovarian cancer is one of the most common reproductive cancers and has the highest mortality rate amongst gynecologic cancers. Because most ovarian cancer diagnoses occur in the late stages of the disease, five-year survival rates fall below 20%. To improve survival rates and to lower mortality rates for ovarian cancer, improved detection at early stages of the disease is needed. Current screening approaches include tumor markers, ultrasound, or a combination. Efforts are underway to discover new biomarkers of ovarian cancer in order to surmount the obstacles in early-stage diagnosis. Among serum protein markers, HE4 and mesothelin can augment CA125 detection providing higher sensitivity and specificity due to the presence of these proteins in early-stage ovarian cancer. Detection testing that includes methylation of the MCJ gene and increased expression of vascular endothelial growth factor is correlated to poor prognosis and may predict patient survival outcome. Detection testing of biomarkers with long-term stability and combination panels of markers, will likely lead to effective screening strategies with high specificity and sensitivity for early detection of ovarian cancer.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.